Development and Clinical Use of Targeted ImmunoPET Imaging for Digestive System Cancers Evaluating Diagnostic Accuracy and Distribution of Specialized Imaging Agents

What this Trial Is About

Researchers are evaluating target-specific immunoPETCT imaging methods for digestive system carcinomas, including various malignant tumors in the digestive tract. This study aims to establish optimal imaging techniques and understand the physiological and pathological distribution of these imaging agents. The diagnostic effectiveness of these agents will be assessed, focusing on their ability to detect malignant tumors in the digestive system. Participants will receive one of several target-specific radioactive probes designed to highlight cancer cells during PETCT scans. These probes include HER2-targeted, Trop2-targeted, GPC3-targeted, GPA33-targeted, and Nectin-4-targeted agents, each given at a dose of 0.05-0.1 mCikg. Whole-body PETCT scans will be performed 1 to 2 hours after injection to visualize tumor uptake, which will be scored both visually and quantitatively. During the study, researchers will measure the distribution of the tracers in the body, including maximum standardized uptake values SUVmax in tumors. They will evaluate diagnostic accuracy by calculating sensitivity, specificity, and predictive values, and correlate tracer uptake with protein expression in tumor tissue. Secondary outcomes include the tracers predictive value for immunotherapies and targeted therapies over 3 to 6 months. Participants will be monitored for radiation dosimetry and safety, with study participation lasting up to several months depending on outcomes assessed.

Target-specific immunoPET Imaging of Digestive System Carcinoma